Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001.

@article{Bernhard2008ClinicalBA,
  title={Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001.},
  author={Juerg Bernhard and Daniel Dietrich and Werner Scheithauer and Daniela Gerber and Gy{\"o}rgy Bodoky and Thomas Ruhstaller and Bengt Glimelius and Emilio Bajetta and Johannes Schueller and Piercarlo Saletti and Jean S Bauer and Ari{\'e} Figer and Bernhard Cornelius Pestalozzi and C L Koehne and Walter Mingrone and Salomon Marcello Stemmer and Karin R. Tamas and Gabriela Verena Kornek and Dieter Koeberle and Richard Herrmann},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2008},
  volume={26 22},
  pages={3695-701}
}
PURPOSE To compare clinical benefit response (CBR) and quality of life (QOL) in patients receiving gemcitabine (Gem) plus capecitabine (Cap) versus single-agent Gem for advanced/metastatic pancreatic cancer. PATIENTS AND METHODS Patients were randomly assigned to receive GemCap (oral Cap 650 mg/m(2) twice daily on days 1 through 14 plus Gem 1,000 mg/m(2) in a 30-minute infusion on days 1 and 8 every 3 weeks) or Gem (1,000 mg/m(2) in a 30-minute infusion weekly for 7 weeks, followed by a 1… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 34 extracted citations

Similar Papers

Loading similar papers…